Cost and cost‐effectiveness of immunotherapy in childhood ALL: A systematic review

Cost and cost‐effectiveness of immunotherapy in childhood ALL: A systematic review

Abstract Survival rates for pediatric acute lymphoblastic leukemia (pALL) have improved dramatically; relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) remains challenging. Immunotherapies are rapidly evolving treatments for r/r ALL with limited cost‐effectiveness data. This study identif...

ver descrição completa

Detalhes bibliográficos
Principais autores: Yolanda Scoleri‐Longo, Petros Pechlivanoglou, Sumit Gupta
Formato: Artigo
Idioma:English
Publicado em: Wiley 2024-02-01
coleção:eJHaem
Assuntos:
acute lymphoblastic leukemia
cancer
child
cost‐effectiveness
immunotherapy
systematic review
Acesso em linha:https://doi.org/10.1002/jha2.814

Internet

https://doi.org/10.1002/jha2.814

Registros relacionados